

## Appendix: Tables

1.	Sales January to December 2020 and 2019.....	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2020 and 2019.....	3
3.	Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth YTD December 2020 vs. YTD December 2019.....	4
4.	Pharmaceuticals Division – New products sales and constant exchange rate growth YTD December 2020 vs. YTD December 2019.....	5
5.	Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD December 2020 vs. YTD December 2019.....	6
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth.....	7
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States.....	8
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe.....	9
9.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan.....	10
10.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*.....	11
11.	Roche Group consolidated income statement for the twelve months ended 31 December 2020.....	12
12.	Roche Group core results reconciliation – Full Year 2020.....	13
13.	Divisional core results reconciliation – Full Year 2020.....	14
14.	Roche Group consolidated balance sheet.....	15
15.	Roche Group consolidated statement of cash flows.....	16

**1. Sales January to December 2020 and 2019**

CHF millions	Twelve months ended 31 December		% change	
	2020	2019	At CER	In CHF
Pharmaceuticals Division	44,532	48,516	-2	-8
United States	23,647	26,711	-6	-11
Europe	8,198	8,453	1	-3
Japan	3,765	4,143	-6	-9
International*	8,922	9,209	7	-3
Diagnostics Division	13,791	12,950	14	6
Roche Group	58,323	61,466	1	-5

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

## 2. Quarterly sales and constant exchange rate sales growth by Division in 2020 and 2019

CHF millions	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019
Pharmaceuticals Division	11,957	8	12,262	7	10,940	-6	11,115	-4	10,215	-7
United States	6,675	11	6,616	3	5,848	-10	5,925	-5	5,258	-13
Europe	2,143	6	2,264	14	1,926	-3	2,078	2	1,930	-8
Japan	1,067	3	948	3	960	-7	894	-13	963	-5
International*	2,072	2	2,434	16	2,206	5	2,218	-2	2,064	11
Diagnostics Division	3,443	1	2,881	5	3,198	2	3,583	18	4,129	28
Roche Group	15,400	6	15,143	7	14,138	-4	14,698	1	14,344	1

\*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

### 3. Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth YTD December 2020 vs. YTD December 2019

Top-selling pharmaceuticals January - December 2020	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Avastin	4,992	-25	1,795	-37	1,252	-27	717	-15	1,228	-2
Ocrevus	4,326	24	3,408	18	674	41	-	-	244	68
MabThera/Rituxan	4,223	-31	2,864	-32	379	-33	64	-39	916	-22
Perjeta	3,883	18	1,476	2	1,150	10	294	9	963	75
Herceptin	3,732	-34	1,356	-47	665	-32	140	-40	1,571	-17
Actemra/RoActemra	2,858	32	1,212	36	783	16	366	-5	497	116
Tecentriq	2,738	55	1,566	40	576	72	330	82	266	93
Hemlibra	2,190	68	1,388	56	373	135	313	40	116	233
Xolair	1,904	2	1,904	2	-	-	-	-	-	-
Kadcyla	1,745	34	807	34	560	35	90	13	288	37

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

4. Pharmaceuticals Division – New products sales and constant exchange rate growth YTD December 2020 vs. YTD December 2019

New products January - December 2020	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Erivedge	278	7	186	6	61	3	-	-	31	18
Perjeta	3,883	18	1,476	2	1,150	10	294	9	963	75
Kadcyla	1,745	34	807	34	560	35	90	13	288	37
Gazyva/Gazyvaro	632	21	293	25	211	26	69	8	59	6
Esbriet	1,108	4	788	3	266	6	-	-	54	5
Cotellic	51	-3	12	16	21	-29	-	-	18	39
Alecensa	1,160	40	343	10	264	29	240	15	313	189
Tecentriq	2,738	55	1,566	40	576	72	330	82	266	93
Ocrevus	4,326	24	3,408	18	674	41	-	-	244	68
Hemlibra	2,190	68	1,388	56	373	135	313	40	116	233
Xofluza	43	370	37	399	-	-	-	-	6	227
Polivy	169	248	104	117	62	**	-	-	3	**
Rozlytrek	24	267	19	198	1	**	4	**	-	-
Phesgo	23	-	23	-	-	-	-	-	-	-
Enspryng	18	-	6	-	-	-	12	-	-	-
Evrysdi	55	-	54	-	-	-	-	-	1	-

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

\*\* Over 500%

5. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD December 2020 vs. YTD December 2019

CHF millions January - December 2020	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Avastin	4,992	-25	1,795	-37	1,252	-27	717	-15	1,228	-2
Ocrevus	4,326	24	3,408	18	674	41	-	-	244	68
MabThera/Rituxan	4,223	-31	2,864	-32	379	-33	64	-39	916	-22
Perjeta	3,883	18	1,476	2	1,150	10	294	9	963	75
Herceptin	3,732	-34	1,356	-47	665	-32	140	-40	1,571	-17
Actemra/RoActemra	2,858	32	1,212	36	783	16	366	-5	497	116
Tecentriq	2,738	55	1,566	40	576	72	330	82	266	93
Hemlibra	2,190	68	1,388	56	373	135	313	40	116	233
Xolair	1,904	2	1,904	2	-	-	-	-	-	-
Kadcyla	1,745	34	807	34	560	35	90	13	288	37
Lucentis	1,444	-16	1,444	-16	-	-	-	-	-	-
Activase/TNKase	1,321	5	1,268	5	-	-	-	-	53	6
Alecensa	1,160	40	343	10	264	29	240	15	313	189
Esbriet	1,108	4	788	3	266	6	-	-	54	5
Pulmozyme	642	-9	437	-12	133	5	1	19	71	-6
Gazyva	632	21	293	25	211	26	69	8	59	6
CellCept	606	-2	62	-21	157	-6	80	-2	307	5
Mircera	470	-17	-	-	58	-9	154	-21	258	-15
Madopar	361	8	-	-	109	0	-	-	252	11
Xeloda	301	-21	7	-68	16	-3	32	-55	246	-10

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

**6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth**

CHF millions	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019
Avastin	1,608	-6	1,497	-13	1,338	-24	1,188	-30	969	-35
Ocrevus	1,044	55	1,112	38	964	12	1,198	37	1,052	10
MabThera/Rituxan	1,518	-6	1,389	-15	1,051	-32	1,003	-33	780	-43
Perjeta	857	16	1,011	22	930	12	988	17	954	20
Herceptin	1,240	-24	1,207	-24	993	-33	879	-38	653	-43
Actemra/RoActemra	605	5	666	30	795	40	673	27	724	29
Tecentriq	578	136	644	99	653	54	718	49	723	35
Hemlibra	459	313	521	146	482	59	572	57	615	45
Xolair	484	0	468	3	490	1	493	3	453	3
Kadcyla	388	57	428	55	409	26	458	33	450	26
Lucentis	456	7	387	-13	341	-25	392	-5	324	-22
Activase/TNKase	312	0	390	11	301	-3	314	1	316	11
Alecensa	220	11	268	43	272	27	301	37	319	54
Esbriet	316	9	292	22	274	2	278	5	264	-9
Pulmozyme	189	-5	191	10	161	-10	148	-16	142	-17
Gazyva	162	51	165	49	145	23	162	15	160	6
CellCept	154	-3	166	7	148	-2	148	-11	144	-1
Mircera	142	5	126	-8	125	-7	118	-26	101	-24
Madopar	84	9	98	5	96	23	86	2	81	4
Xeloda	87	-13	86	-16	90	-12	77	-20	48	-42

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019
Avastin	647	-11	586	-27	471	-39	432	-37	306	-47
Ocrevus	833	44	898	29	773	9	939	32	798	5
MabThera/Rituxan	1,099	1	973	-14	720	-33	672	-35	499	-49
Perjeta	370	4	395	-1	375	4	368	7	338	0
Herceptin	533	-24	475	-38	373	-46	313	-49	195	-59
Actemra/RoActemra	248	6	296	44	396	65	250	15	270	19
Tecentriq	343	146	376	79	368	31	422	37	400	27
Hemlibra	308	302	353	119	311	51	356	50	368	30
Xolair	484	0	468	3	490	1	493	3	453	3
Kadcyla	187	108	204	68	200	36	213	34	190	11
Lucentis	456	7	387	-13	341	-25	392	-5	324	-22
Activase/TNKase	297	-1	376	10	288	-3	302	1	302	11
Alecensa	98	23	84	29	84	7	89	17	86	-4
Esbriet	233	6	202	20	200	4	200	8	186	-12
Pulmozyme	136	-4	128	10	116	-10	99	-22	94	-24
Gazyva	74	48	79	48	65	23	78	29	71	5
CellCept	17	-15	18	-15	14	-31	15	-29	15	-6
Mircera	-	-	-	-	-	-	-	-	-	-
Madopar	-	-	-	-	-	-	-	-	-	-
Xeloda	4	-53	3	-71	-1	-	3	-15	2	-51



8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019
Avastin	439	1	423	-3	373	-13	286	-33	170	-61
Ocrevus	157	112	156	79	141	26	193	56	184	20
MabThera/Rituxan	120	-33	123	-24	79	-44	102	-29	75	-36
Perjeta	287	21	307	21	260	1	291	13	292	4
Herceptin	212	-39	193	-32	168	-33	161	-30	143	-31
Actemra/RoActemra	178	3	209	27	173	2	186	10	215	24
Tecentriq	122	172	145	169	137	90	155	72	139	18
Hemlibra	57	202	78	216	68	92	115	171	112	99
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	120	28	132	43	125	26	147	39	156	34
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Alecensa	59	58	66	51	59	27	68	22	71	22
Esbriet	69	16	74	28	60	-3	64	-2	68	2
Pulmozyme	33	-2	37	12	31	0	31	3	34	4
Gazyva	50	38	56	57	45	13	54	26	56	15
CellCept	43	-1	48	15	32	-20	39	-8	38	-10
Mircera	16	-8	17	6	14	-13	14	-14	13	-17
Madopar	29	7	29	13	24	-11	28	2	28	-2
Xeloda	4	7	5	25	4	4	3	-18	4	-18

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019
Avastin	206	-13	181	-5	182	-19	171	-25	183	-7
Ocrevus	-	-	-	-	-	-	-	-	-	-
MabThera/Rituxan	25	-37	17	-39	16	-45	15	-38	16	-34
Perjeta	79	67	74	49	75	11	70	-9	75	0
Herceptin	58	-15	40	-26	37	-45	32	-46	31	-43
Actemra/RoActemra	103	1	89	6	92	-8	86	-15	99	1
Tecentriq	63	68	69	111	79	94	77	62	105	75
Hemlibra	79	472	74	207	77	36	76	13	86	15
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	20	-5	18	3	23	3	22	7	27	41
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Alecensa	55	-1	53	15	62	8	58	8	67	29
Esbriet	-	-	-	-	-	-	-	-	-	-
Pulmozyme	1	14	-	-	-	-	1	40	-	-
Gazyva	20	145	15	95	21	65	15	-36	18	-9
CellCept	22	-1	19	0	21	-6	19	-3	21	1
Mircera	51	-14	37	-17	38	-29	39	-20	40	-18
Madopar	-	-	-	-	-	-	-	-	-	-
Xeloda	14	-53	10	-54	8	-60	7	-56	7	-50

10. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International\*

CHF millions	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019
Avastin	316	0	307	5	312	-6	299	-14	310	8
Ocrevus	54	155	58	119	50	43	66	74	70	55
MabThera/Rituxan	274	-11	276	-9	236	-25	214	-30	190	-24
Perjeta	121	19	235	83	220	50	259	52	249	135
Herceptin	437	-16	499	4	415	-14	373	-28	284	-29
Actemra/RoActemra	76	15	72	27	134	123	151	209	140	114
Tecentriq	50	109	54	101	69	120	64	74	79	86
Hemlibra	15	**	16	**	26	319	25	58	49	325
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	61	50	74	63	61	12	76	30	77	50
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	15	8	14	27	13	4	12	-5	14	1
Alecensa	8	-64	65	97	67	107	86	141	95	**
Esbriet	14	31	16	23	14	3	14	5	10	-9
Pulmozyme	19	-15	26	8	14	-25	17	-6	14	-7
Gazyva	18	43	15	7	14	16	15	5	15	-1
CellCept	72	-1	81	11	81	18	75	-10	70	4
Mircera	75	28	72	-6	73	13	65	-31	48	-30
Madopar	55	11	69	2	72	40	58	2	53	6
Xeloda	65	10	68	1	79	8	64	-13	35	-41

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

\*\* Over 500%

## 11. Roche Group consolidated income statement for the twelve months ended 31 December 2020

in millions of CHF	Pharma- ceuticals	Diagnostics	Corporate	Group
<b>Sales</b>	<b>44,532</b>	<b>13,791</b>	-	<b>58,323</b>
Royalties and other operating income	1,959	61	-	2,020
Cost of sales	(9,483)	(6,694)	-	(16,177)
Marketing and distribution	(6,796)	(2,776)	-	(9,572)
Research and development	(11,421)	(1,588)	-	(13,009)
General and administration	(1,639)	(793)	(610)	(3,042)
<b>Operating profit</b>	<b>17,152</b>	<b>2,001</b>	<b>(610)</b>	<b>18,543</b>
Financing costs				(553)
Other financial income (expense)				(25)
<b>Profit before taxes</b>				<b>17,965</b>
Income taxes				(2,897)
<b>Net income</b>				<b>15,068</b>
Attributable to				
- Roche shareholders				14,295
- Non-controlling interests				773
<b>Earnings per share and non-voting equity security</b>				
Basic (CHF)				16.73
Diluted (CHF)				16.52

## 12. Roche Group core results reconciliation – Full Year 2020

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Global issues	Normalisation of ECP tax benefit	Core
<b>Sales</b>	<b>58,323</b>	-	-	-	-	-	-	-	-	<b>58,323</b>
Royalties and other operating income	2,020	-	-	-	-	-	-	-	-	2,020
Cost of sales	(16,177)	225	1,304	81	-	-	-	-	-	(14,567)
Marketing and distribution	(9,572)	178	33	-	-	-	-	-	-	(9,361)
Research and development	(13,009)	99	413	344	-	-	-	-	-	(12,153)
General and administration	(3,042)	407	-	247	9	(345)	(2)	-	-	(2,726)
<b>Operating profit</b>	<b>18,543</b>	<b>909</b>	<b>1,750</b>	<b>672</b>	<b>9</b>	<b>(345)</b>	<b>(2)</b>	-	-	<b>21,536</b>
Financing costs	(553)	-	-	-	7	7	-	-	-	(539)
Other financial income (expense)	(25)	-	-	-	-	-	-	-	-	(25)
<b>Profit before taxes</b>	<b>17,965</b>	<b>909</b>	<b>1,750</b>	<b>672</b>	<b>16</b>	<b>(338)</b>	<b>(2)</b>	-	-	<b>20,972</b>
Income taxes	(2,897)	(168)	(482)	(94)	(12)	67	-	-	(8)	(3,594)
<b>Net income</b>	<b>15,068</b>	<b>741</b>	<b>1,268</b>	<b>578</b>	<b>4</b>	<b>(271)</b>	<b>(2)</b>	-	<b>(8)</b>	<b>17,378</b>
Attributable to										
- Roche shareholders	14,295	719	1,262	578	4	(271)	(2)	-	(8)	16,577
- Non-controlling interests	773	22	6	-	-	-	-	-	-	801
EPS - diluted (CHF)	16.52	0.83	1.46	0.67	-	(0.31)	-	-	(0.01)	19.16

### 13. Divisional core results reconciliation – Full Year 2020

in millions of CHF	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Core
<b>Pharmaceuticals</b>								
Sales	44,532	-	-	-	-	-	-	44,532
Royalties and other operating income	1,959	-	-	-	-	-	-	1,959
Cost of sales	(9,483)	122	1,210	81	-	-	-	(8,070)
Marketing and distribution	(6,796)	139	24	-	-	-	-	(6,633)
Research and development	(11,421)	75	405	344	-	-	-	(10,597)
General and administration	(1,639)	237	-	-	34	(344)	(2)	(1,714)
<b>Operating profit</b>	<b>17,152</b>	<b>573</b>	<b>1,639</b>	<b>425</b>	<b>34</b>	<b>(344)</b>	<b>(2)</b>	<b>19,477</b>
<b>Diagnostics</b>								
Sales	13,791	-	-	-	-	-	-	13,791
Royalties and other operating income	61	-	-	-	-	-	-	61
Cost of sales	(6,694)	103	94	-	-	-	-	(6,497)
Marketing and distribution	(2,776)	39	9	-	-	-	-	(2,728)
Research and development	(1,588)	24	8	-	-	-	-	(1,556)
General and administration	(793)	56	-	247	(25)	8	-	(507)
<b>Operating profit</b>	<b>2,001</b>	<b>222</b>	<b>111</b>	<b>247</b>	<b>(25)</b>	<b>8</b>	<b>-</b>	<b>2,564</b>
<b>Corporate</b>								
General and administration	(610)	114	-	-	-	(9)	-	(505)
<b>Operating profit</b>	<b>(610)</b>	<b>114</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(9)</b>	<b>-</b>	<b>(505)</b>

## 14. Roche Group consolidated balance sheet

in millions of CHF	31 December 2020	31 December 2019*	31 December 2018
<b>Non-current assets</b>			
Property, plant and equipment	22,158	22,173	21,818
Right-of-use assets	1,112	1,145	0
Goodwill	9,249	10,295	8,948
Intangible assets	12,017	10,751	9,346
Deferred tax assets	5,459	4,979	3,895
Defined benefit plan assets	967	945	877
Other non-current assets	2,234	1,549	1,389
<b>Total non-current assets</b>	<b>53,196</b>	<b>51,837</b>	<b>46,273</b>
<b>Current assets</b>			
Inventories	7,194	6,055	6,621
Accounts receivable	10,154	10,440	9,776
Current income tax assets	149	237	208
Other current assets	3,111	2,664	2,521
Marketable securities	6,607	5,783	6,437
Cash and cash equivalents	5,727	6,075	6,681
<b>Total current assets</b>	<b>32,942</b>	<b>31,254</b>	<b>32,244</b>
<b>Total assets</b>	<b>86,138</b>	<b>83,091</b>	<b>78,517</b>
<b>Non-current liabilities</b>			
Long-term debt	(10,220)	(12,668)	(16,077)
Net deferred tax liabilities	(353)	(298)	(384)
Defined benefit plan liabilities	(7,831)	(7,480)	(7,017)
Provisions	(1,453)	(1,515)	(1,452)
Other non-current liabilities	(1,107)	(1,144)	(188)
<b>Total non-current liabilities</b>	<b>(20,964)</b>	<b>(23,105)</b>	<b>(25,118)</b>
<b>Current liabilities</b>			
Short-term debt	(3,996)	(1,695)	(2,693)
Current income tax liabilities	(3,679)	(3,838)	(3,808)
Provisions	(1,836)	(2,885)	(2,329)
Accounts payable	(4,121)	(3,822)	(3,526)
Other current liabilities	(11,769)	(11,879)	(10,677)
<b>Total current liabilities</b>	<b>(25,401)</b>	<b>(24,119)</b>	<b>(23,033)</b>
<b>Total liabilities</b>	<b>(46,365)</b>	<b>(47,224)</b>	<b>(48,151)</b>
<b>Total net assets</b>	<b>39,773</b>	<b>35,867</b>	<b>30,366</b>
<b>Equity</b>			
Capital and reserves attributable to Roche shareholders	36,341	32,747	27,622
Equity attributable to non-controlling interests	3,432	3,120	2,744
<b>Total equity</b>	<b>39,773</b>	<b>35,867</b>	<b>30,366</b>

\* The balance sheet at 31 December 2019 has been restated following the finalisation of the valuation of the net assets acquired related to the Spark Therapeutics acquisition in 2019.

## 15. Roche Group consolidated statement of cash flows

in millions of CHF	FY 2020	FY 2019
<b>Cash flows from operating activities</b>		
Cash generated from operations	25,614	26,793
(Increase) decrease in net working capital	(2,060)	149
Payments made for defined benefit plans	(601)	(676)
Utilisation of provisions	(1,390)	(828)
Disposal of products	239	490
Other operating cash flows	-	-
<b>Cash flows from operating activities, before income taxes paid</b>	<b>21,802</b>	<b>25,928</b>
Income taxes paid	(3,236)	(3,543)
<b>Total cash flows from operating activities</b>	<b>18,566</b>	<b>22,385</b>
<b>Cash flows from investing activities</b>		
Purchase of property, plant and equipment	(3,528)	(3,503)
Purchase of intangible assets	(3,162)	(1,393)
Disposal of property, plant and equipment	70	71
Disposal of intangible assets	-	2
Business combinations	(1,179)	(4,706)
Divestment of subsidiaries	3	3
Interest and dividends received	16	69
Sales of marketable securities	353	587
Purchases of marketable securities	(169)	(221)
Sales (purchases) of money market instruments and time accounts over three months, net	(1,181)	461
Other investing cash flows	(290)	(4)
<b>Total cash flows from investing activities</b>	<b>(9,067)</b>	<b>(8,634)</b>
<b>Cash flows from financing activities</b>		
Proceeds from issue of bonds and notes	-	-
Redemption and repurchase of bonds and notes	-	(5,414)
Increase (decrease) in commercial paper	318	858
Increase (decrease) in other debt	341	153
Hedging and collateral arrangements	557	(137)
Changes in ownership interests in subsidiaries	-	(21)
Changes in non-controlling interests	-	-
Equity contribution by non-controlling interests - capital injection	-	13
Interest paid	(422)	(624)
Principal portion of lease liabilities paid	(369)	(372)
Dividends paid	(7,964)	(7,682)
Equity-settled equity compensation plans, net of transactions in own equity	(2,126)	(947)
Other financing cash flows	(1)	-
<b>Total cash flows from financing activities</b>	<b>(9,666)</b>	<b>(14,173)</b>
Net effect of currency translation on cash and cash equivalents	(181)	(184)
<b>Increase (decrease) in cash and cash equivalents</b>	<b>(348)</b>	<b>(606)</b>
Cash and cash equivalents at beginning of period	6,075	6,681
<b>Cash and cash equivalents at end of period</b>	<b>5,727</b>	<b>6,075</b>